50 mg ABX-464 (n=6)		150 mg ABX-464 (n=16)		Placebo (n=8)
	E	n (%)	E	n(%)	E	n (%)
Any treatment-emergent adverse events	10	4 (66.7%)	58	15 (93.8%)	13	3 (37.5%)
Blood and lymphatic system disorders	2	1 (16.7%)	0	0	0	0
Lymphadenopathy	2	1 (16.7%)	0	0	0	0
Gastrointestinal disorders	2	1 (16.7%)	23	13 (81.3%)	1	1 (12.5%)
Abdominal pain	0	0	4	3 (18.8%)	0	0
Abdominal pain upper	0	0	5	4 (25.0%)	0	0
Diarrhoea	2	1 (16.7%)	5	3 (18.8%)	0	0
Epigastric discomfort	0	0	1	1 (6.3%)	0	0
Gastric disorder	0	0	1	1 (6.3%)	0	0
Gastro-oesophageal reflux disease	0	0	1	1 (6.3%)	0	0
Nausea	0	0	2	2 (12.5%)	1	1 (12.5%)
Rectal haemorrhage	0	0	1	1 (6.3%)	0	0
Salivary gland disorder	0	0	1	1 (6.3%)	0	0
Tooth infection	0	0	1	1 (6.3%)	0	0
Toothache	0	0	1	1 (6.3%)	0	0
General disorders and administration site conditions	2	1 (16.7%)	10	6 (37.5%)	1	1 (12.5%)
Fatigue	0	0	5	3 (18.8%)	0	0
Inflammation	1	1 (16.7%)	0	0	0	0
Influenza like illness	1	1 (16.7%)	1	1 (6.3%)	0	0
Malaise	0	0	1	1 (6.3%)	0	0
Oedema peripheral	0	0	2	1 (6.3%)	0	0
Peripheral swelling	0	0	1	1 (6.3%)	0	0
Pyrexia	0	0	0	0	1	1 (12.5%)
Infections	0	0	3	3 (18.8%)	7	3 (37.5%)
Bronchitis	0	0	0	0	1	1 (12.5%)
Eye infection	0	0	0	0	1	1 (12.5%)
Nasopharyngitis	0	0	0	0	2	2 (25.0%)
Pharyngitis	0	0	0	0	1	1 (12.5%)
Rhinitis	0	0	1	1 (6.3%)	0	0
Sinusitis	0	0	1	1 (6.3%)	1	1 (12.5%)
Syphilis	0	0	0	0	1	1 (12.5%)
Upper respiratory tract infection	0	0	1	1 (6.3%)	0	0
Injury, poisoning and procedural complications	2	2 (33.3%)	0	0	0	0
Contusion	1	1 (16.7%)	0	0	0	0
Scar	1	1 (16.7%)	0	0	0	0
Investigations	0	0	2	2 (12.5%)	1	1 (12.5%)
Activated partial thromboplastin time prolonged	0	0	1	1 (6.3%)	0	0
C-reactive protein increased	0	0	1	1 (6.3%)	1	1 (12.5%)
Metabolism and nutrition disorders	0	0	1	1 (6.3%)	0	0
Gout	0	0	1	1 (6.3%)	0	0
Musculoskeletal and connective tissue disorders	0	0	10	8 (50.0%)	2	2 (25.0%)
Arthralgia	0	0	3	2 (12.5%)	1	1 (12.5%)
Back pain	0	0	6	5 (31.3%)	0	0
Myalgia	0	0	0	0	1	1 (12.5%)
Pain in extremity	0	0	1	1 (6.3%)	0	0
Nervous system disorders	2	2 (33.3%)	7	5 (31.3%)	0	0
Headache	2	2 (33.3%)	7	5 (31.3%)	0	0
Psychiatric disorders	0	0	1	1 (6.3%)	0	0
Insomnia	0	0	1	1 (6.3%)	0	0
Renal and urinary disorders	0	0	1	1 (6.3%)	0	0
Dysuria	0	0	1	1 (6.3%)	0	0
Skin and subcutaneous tissue disorders	0	0	0	0	1	1 (12.5%)
Rash	0	0	0	0	1	1 (12.5%)

E: events; n: number of participants